References: Risk factors for VTE

  • Australian Commission on Safety and Quality in Health Care (ACSQHC). Evidence sources: venous thromboembolism prevention. Clinical care standard. Sydney: ACSQHC; 2018. https://www.safetyandquality.gov.au/standards/clinical-care-standards/venous-thromboembolism-prevention-clinical-care-standard
  • Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e195S-e226S. https://www.ncbi.nlm.nih.gov/pubmed/22315261
  • Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022. https://www.ncbi.nlm.nih.gov/pubmed/36017568
  • National Institute for Health and Clinical Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism [ng89]. London: NICE; 2018 (updated 2019). https://www.nice.org.uk/guidance/ng89
  • Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 2019;210(5):227-35. https://www.ncbi.nlm.nih.gov/pubmed/30739331
  • Ye F, Bell LN, Mazza J, Lee A, Yale SH. Variation in Definitions of Immobility in Pharmacological Thromboprophylaxis Clinical Trials in Medical Inpatients: A Systematic Review. Clin Appl Thromb Hemost 2018;24(1):13-21. https://www.ncbi.nlm.nih.gov/pubmed/28301904